BERGENBIO TO PRESENT AN UPDATE ON THE ONGOING PHASE II STUDY OF BEMCENTINIB IN COMBINATION WITH PEMBROLIZUMAB IN REFRACTORY NSCLC AT WCLC 2020
Bergen, Norway, 16 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce it has been accepted for an oral presentation at the 2020 World Conference on Lung Cancer Singapore (WCLC), being held from 28-31 January 2021. The oral presentation will provide an update from the Company's Phase II study of bemcentinib in combination with anti-PD-1 therapy pembrolizumab (BGBC008) in refractory non-small cell lung cancer (NSCLC). Abstract titles have been